Field & Main Bank Purchases New Position in Medtronic PLC (MDT)

Field & Main Bank purchased a new stake in Medtronic PLC (NYSE:MDT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,285 shares of the medical technology company’s stock, valued at approximately $572,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc boosted its stake in shares of Medtronic by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 109,447,687 shares of the medical technology company’s stock worth $10,766,369,000 after acquiring an additional 1,199,118 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Medtronic by 1.5% during the 4th quarter. BlackRock Inc. now owns 98,921,138 shares of the medical technology company’s stock worth $8,997,868,000 after acquiring an additional 1,487,997 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Medtronic by 1.3% during the 4th quarter. Bank of New York Mellon Corp now owns 17,225,948 shares of the medical technology company’s stock worth $1,566,873,000 after acquiring an additional 213,593 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Medtronic by 10.2% during the 4th quarter. Geode Capital Management LLC now owns 16,690,207 shares of the medical technology company’s stock worth $1,515,557,000 after acquiring an additional 1,538,130 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Medtronic by 4.3% during the 4th quarter. Northern Trust Corp now owns 16,526,215 shares of the medical technology company’s stock worth $1,503,225,000 after acquiring an additional 688,537 shares in the last quarter. Institutional investors own 81.52% of the company’s stock.

Several brokerages have recently commented on MDT. Zacks Investment Research raised Medtronic from a “sell” rating to a “hold” rating in a research note on Monday. Citigroup boosted their price target on Medtronic from $95.00 to $101.00 and gave the stock a “neutral” rating in a research note on Monday, February 25th. Barclays reissued a “buy” rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 20th. Northland Securities restated a “hold” rating and set a $84.00 price objective on shares of Medtronic in a research report on Monday, March 18th. Finally, Oppenheimer set a $104.00 price objective on Medtronic and gave the stock a “buy” rating in a research report on Wednesday, February 20th. Ten analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $103.39.

MDT traded up $0.99 during trading on Wednesday, hitting $88.76. The company’s stock had a trading volume of 5,965,308 shares, compared to its average volume of 5,811,958. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.92 and a current ratio of 2.36. The company has a market capitalization of $117.66 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 2.18 and a beta of 0.78. Medtronic PLC has a twelve month low of $81.66 and a twelve month high of $100.15.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 19th. The medical technology company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.05. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.53 billion. Medtronic had a return on equity of 13.85% and a net margin of 16.10%. Medtronic’s revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.17 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.15 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Field & Main Bank Purchases New Position in Medtronic PLC (MDT)” was originally posted by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://sundanceherald.com/2019/05/22/6285-shares-in-medtronic-plc-mdt-purchased-by-field-main-bank.html.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Article: Do investors pay a separate front-end load every time they buy additional shares?

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply